Critical Review: Positron (POSC) & Its Rivals

Institutional & Insider Ownership

44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by company insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Positron and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Positron	$740,000.00	-$1.64 million	-11.99
Positron Competitors	$984.82 million	$83.13 million	10.66

Positron’s rivals have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Positron and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Positron	-300.00%	N/A	-89.57%
Positron Competitors	-298.69%	-83.99%	-27.42%

Volatility and Risk

Positron has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Positron’s rivals have a beta of 0.91, meaning that their average stock price is 9% less volatile than the S&P 500.

Summary

Positron rivals beat Positron on 7 of the 9 factors compared.

Positron Company Profile

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.